Drug Profile
Mirabegron - Astellas Pharma
Alternative Names: Betanis; Betmiga; Betmiga PR; Myrbetriq; Myrbetriq Granules; YM-178Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Acetamides; Antihyperglycaemics; Erectile dysfunction therapies; Ethanolamines; Small molecules; Thiazoles; Urologics
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Overactive bladder
- Phase III Interstitial cystitis
- Phase I/II Erectile dysfunction
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 24 Jul 2023 Astellas Pharma terminates phase-III trial in Overactive bladder (In children, In adolescent) in Belgium, Netherlands, South Korea, Norway, France, Italy, Poland, Denmark , Spain, Germany, Russia, Turkey (PO, Suspension) due to operational futility (NCT04641975)
- 26 Jun 2023 Phase-III clinical trials in Overactive bladder (In children, In infants) in Turkey, Poland, Denmark, Philippines (PO) (NCT05621616) (EudraCT2021-005455-37)
- 26 Jun 2023 Astellas Pharma initiates enrolment in a phase III trial for Overactive bladder (In children, In infants) in Belgium (PO) (NCT05621616) (EudraCT2021-005455-37)